Hester Biosciences Ltd

Hester Biosciences Investor Presentation: Key Takeaways

Standalone revenue +28% Q2, +21% H1; PAT +131% Q2. EBITDA margin 35%, gross margin 78%. H1 consolidated PAT boosted by one-time Africa loan gain.

Hester Biosciences Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 44.1% YoY

Hester Biosciences Ltd reported revenue from operations of ₹97.9 Cr (+37.9% YoY) and net profit of ₹20.6 Cr (+44.1% YoY) for Q2 FY27.

Key figure

Net profit ₹20.6 Cr · +44.1% YoY

Hester Biosciences Board Meeting Date

Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.

Hester Biosciences Management Change

Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.

Hester Biosciences Other Announcement

Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.

Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment

Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.

Value

₹1.05 Cr

Execution

six months

Hester Biosciences Promoter Reclassification

Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.

Hester Biosciences Annual General Meeting

Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.

Hester Biosciences Credit Rating

Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.